CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

Background: Targeting tumour necrosis factor α (TNF-α) has demonstrated efficacy in Crohn’s disease. Aim: To evaluate CDP571, a humanised antibody to TNF-α, for treating active Crohn’s disease. Patients: A total of 396 patients with moderate to severe Crohn’s disease. Methods: In a 28 week, randomis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sandborn, W J, Feagan, B G, Radford-Smith, G, Kovacs, A, Enns, R, Innes, A, Patel, J
Formato: Artigo
Idioma:Inglês
Publicado em: Copyright 2004 by Gut 2004
Assuntos:
Inflammatory Bowel Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1774244/
https://ncbi.nlm.nih.gov/pubmed/15361500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2003.035253
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados